Thông tin thuốc gốc
Chỉ định và Liều dùng
Drug-induced extrapyramidal symptoms
Adult: As biperiden HCl: 2 mg 1-3 times daily.
Elderly: Lower initial dose and increase gradually to the lowest effective dose.

Adult: As biperiden HCl: Initially, 2 mg 3-4 times daily, may increase according to response. Max: 16 mg/day.
Elderly: Lower initial dose and increase gradually to the lowest effective dose.

Drug-induced extrapyramidal symptoms, Parkinsonism
Adult: As biperiden lactate: Up to 10-20 mg daily by IM or slow IV inj.
Elderly: Lower initial dose and increase gradually to the lowest effective dose.
Cách dùng
Should be taken with food.
Chống chỉ định
Untreated narrow-angle glaucoma, mechanical stenoses in the GI tract, paralytic ileus, megacolon, prostatic adenoma and diseases that can lead to perilous tachycardia.
Thận trọng
Patient w/ thyrotoxicosis, cardiac failure, tachycardia, and those at risk of convulsions. Avoid abrupt withdrawal. Elderly. Pregnancy and lactation.
Phản ứng phụ
Urinary retention, dry mouth, constipation, nausea, vomiting, dyspepsia, blurred vision, mydriasis, dry eyes, tachycardia, arrhythmia, dizziness, drowsiness, headache, hallucinations, memory impairment, confusion, insomnia, worsening of dyskinesia, generalised choreic movements, fever due to anhidrosis, rash, flushed skin, dry skin, hypersensitivity reactions.
Thông tin tư vấn bệnh nhân
This drug may cause drowsiness, dizziness or blurred vision, if affected, do not drive or operate machinery.
Quá liều
Symptoms: Mydriasis, dryness of mucous membranes, flushing, increased heart rate, reduced bowel motility, reduced ureter and bladder tone, increased temp, excitation, confusion, clouding of consciousness and/or hallucinations; cardiac and resp depression in severe overdosage. Management: Supportive treatment. Gastric lavage or emesis may be considered. May give acetylcholinesterase inhibitor as an antidote. Artificial ventilation, reduction of fever and application of a bladder emptying catheter may be necessary. May administer a cardiac stimulant (e.g. dobutamine) if cardiac depression occurs.
Tương tác
Increased CNS and peripheral side effects w/ anticholinergic psychotropic drugs, antihistamines, other antiparkinsonian drugs and antispasmodics. May potentiate dyskinesia w/ levodopa. Increased anticholinergic effects w/ quinidine. May reduce the effect of metoclopramide and other compounds w/ similar activity on the GI tract. May antagonise the therapeutic effects of anticholinesterases.
Food Interaction
Alcohol may enhance the CNS effects of biperiden.
Tác dụng
Description: Biperiden is an anticholinergic agent w/ marked effect on the CNS which is important for its therapeutic application and has weak peripheral vegetative effects. The mechanism of action is considered to relate to competitive antagonism of acetylcholine at cholinergic receptors in the corpus striatum, which then restores the balance.
Absorption: Readily absorbed from the GI tract. Bioavailability: Approx 30%.
Metabolism: Undergoes extensive first-pass metabolism.
Excretion: Elimination half-life: Approx 20 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Biperiden, CID=2381, (accessed on Mar. 9, 2020)

Bảo quản
Store between 15-30°C. Protect from light.
Phân loại MIMS
Biperiden, CID=2381. National Center for Biotechnology Information. PubChem Database. Accessed 18/11/2014.

Buckingham R (ed). Biperiden. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 18/11/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Biperiden. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 23/11/2014.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Biperiden từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Akineton LP
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in